Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
31 results about "Cell Migration Inhibition" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Phenomenon of cell-mediated immunity measured by in vitro inhibition of the migration or phagocytosis of antigen-stimulated LEUKOCYTES or MACROPHAGES. Specific CELL MIGRATION ASSAYS have been developed to estimate levels of migration inhibitory factors, immune reactivity against tumor-associated antigens, and immunosuppressive effects of infectious microorganisms.
Cell migration inhibiting compositions and methods and compositions for treating cancer
Methods for treating an individual having cancer are provided. The method may include administering a cell migration inhibitor and a chemotherapeutic agent to the individual to inhibit migration of cancer cell. Inhibiting cell migration may increase cell division. In this manner, the cell migration inhibitor and the chemotherapeutic agent in combination may have increased efficacy compared to the chemotherapeutic agent alone due to the increased cell division. The cell migration inhibitor may include any of the inhibitors described herein. For example, the cell migration inhibitor may be an organic molecule having a molecular weight of less than about 700, a monoclonal antibody, or a natural product.
Owner:AVOLIX PHARMA
Intraocular Lens Cell Migration Inhibition System
InactiveUS20120232649A1Inhibit migrationReduce posterior capsule opacificationEye treatmentTissue regenerationPosterior capsular opacificationLens epithelial cell
Generally, an intraocular implant and methods for treating an ocular condition. In particular, an intraocular implant which implanted between an intraocular lens and the surface of the posterior capsule of the eye inhibits migration of residual lens epithelial cells after cataract surgery by providing structural barriers to reduce posterior capsule opacification of the eye.
Owner:INSIGHT INNOVATIONS
Intraocular implant cell migration inhibition system
InactiveUS20110295367A1Inhibit migrationReduce posterior capsule opacificationEye surgeryTissue regenerationPosterior capsular opacificationLens epithelial cell
Generally, an intraocular implant and methods for treating an ocular condition. In particular, an intraocular implant which implanted between an intraocular lens and the surface of the posterior capsule of the eye inhibits migration of residual lens epithelial cells after cataract surgery by providing structural barriers to reduce posterior capsule opacification of the eye.
Owner:INSIGHT INNOVATIONS
Protein markers for cardiovascular events
InactiveCN101889205AUse to reduce or preventReduce or prevent the risk of cardiovascular eventsDisease diagnosisBiological testingCathepsin SMacrophage migration inhibitory factor
The present invention relates to a method for predicting the risk of a subject developing a cardiovascular event comprising detecting at least one biomarker in (a sample of) the cardiovascular system from said subject, wherein said biomarker comprises at least one protein selected from the group consisting of Tumor Necrosis Factor Alpha Precursor; Lysosomal-associated Membrane Protein (1); Interleukin-5 Precursor; Interleukin-6 Precursor; C-C Motif Chemokine (2) Precursor; C-C Motif Chemokine (5) Precursor RANTES; Cathepsin L1 Precursor; Adenylate Kinase (1); Leukotriene B4 Receptor (1); Complement Factor D; Secreted Phosphoprotein (1); Small Inducible Cytokine A17 Precursor; C-X-C Motif Chemokine (10) Precursor; Tumor Necrosis Factor Ligand Superfamily Member (11)(RANKL); C-C Motif Chemokine (18) Precursor; 72 kDa Type IVCollagenase Precursor; Neutrophil Collagenase Precursor; fatty acid binding protein (4); calpain (2), (m / II) large subunit; Macrophage Migration Inhibitory Factor; Cathepsin S Precursor; Interleukin (13) Precursor; and soluble ICAM-1.
Owner:卡瓦迪斯有限责任公司
Cell migration inhibiting compositions and methods and compositions for treating cancer
Methods for treating an individual having cancer are provided. The method may include administering a cell migration inhibitor and a chemotherapeutic agent to the individual to inhibit migration of cancer cell. Inhibiting cell migration may increase cell division. In this manner, the cell migration inhibitor and the chemotherapeutic agent in combination may have increased efficacy compared to the chemotherapeutic agent alone due to the increased cell division. The cell migration inhibitor may include any of the inhibitors described herein. For example, the cell migration inhibitor may be an organic molecule having a molecular weight of less than about 700, a monoclonal antibody, or a natural product.
Owner:AVOLIX PHARMA
Intraocular Lens Cell Migration Inhibition System
ActiveUS20130304205A1Inhibit migrationReduce posterior capsule opacificationEye treatmentTissue regenerationPosterior capsular opacificationLens epithelial cell
Owner:INSIGHT INNOVATIONS
Intraocular implant cell migration inhibition system
InactiveUS8551167B2Inhibit migrationReduce posterior capsule opacificationEye surgeryTissue regenerationPosterior capsular opacificationLens epithelial cell
Owner:INSIGHT INNOVATIONS
Cell Migration Inhibition System
InactiveUS20140288645A1Inhibit migrationReduce posterior capsule opacificationEye treatmentTissue regenerationPosterior capsular opacificationLens epithelial cell
Owner:INSIGHT INNOVATIONS
Application of PNO1 inhibitor to preparation of esophagus cancer treatment medicines
ActiveCN110656111AInhibition of proliferation rateInhibition of clonogenicityFermentationAntineoplastic agentsCell invasionPharmaceutical drug
The invention relates to an application of a PNO1 inhibitor to preparation of esophagus cancer treatment medicines, belongs to the field of biopharmaceutical research, and particularly relates to an application of a PNO1 inhibitor to preparation of esophagus cancer treatment medicines. The inventor firstly finds that the PNO1 can be used as an esophagus cancer treatment target point. The PNO1 inhibitor can restrain the proliferation rate of esophagus cancer cells, can restrain the cloning and forming capacity of the esophagus cancer cells, can promote esophagus cancer apoptosis, can restrain esophagus cancer cell migration, can restrain esophagus cancer cell transfer, and can restrain esophagus cancer cell invasion and transfer, so as to treat esophagus cancer, and a new direction is opened up for treatment of esophagus cancer.
Owner:THE FIRST AFFILIATED HOSPITAL OF BENGBU MEDICAL COLLEGE
Novel methods for the treatment of inflammatory diseases
Methods of inhibiting the cytokine or biological activity of Macrophage Migration Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) are provided. The invention also relates to methods of treating diseases or conditions where MIF cytokine or biological activity is implicated comprising administration of compounds of formula (I), either alone or as a part of combination therapy. Novel compounds of formula (I) are also provided for.
Owner:CORTICAL PTY LTD
Novel Methods for the Treatment of Inflammatory Diseases
Owner:CORTICAL PTY LTD
Method for preparing anti-MIF antibodies
InactiveUS20060191024A1Antibacterial agentsOrganic active ingredientsHigh affinity antibodyAnti-CEA Antibody
The specification provides methods of preparing high-affinity antibodies to a macrophage migration inhibitory factor (MIF) in animals in which the MIF gene has been homozygously knocked-out (MIF− / −). Also provided are methods of preparing hybridomas which produce the anti-MIF antibodies, methods of administering the antibodies to treat inflammatory or cancerous conditions and / or diseases modulated by MIF, as well as compositions comprising said high-affinity anti-MIF antibodies.
Owner:BAXALTA GMBH
Application of IC-4 in antiangiogenesis
The invention discloses an application of a compound IC-4 with the structural formula represented by formula (I) or its salts in antiangiogenesis, and further discloses an application of the compound IC-4 with the structural formula represented by formula (I) or its salt in preparation of antiangiogenic agents. Researches on the application of the IC-4 or its salt in the antiangiogenesis are based on researches on growth factor induced endothelial cell growth inhibition, angiogenesis inhibition, endothelial cell migration inhibition and endothelial cell transfer inhibition of the IC-4 or its salts, and combine with a scientific and reasonable research system constructed through integral experiments of zebra fish embryo angiogenesis.
Owner:UNIVERSITY OF MACAU +1
Polypeptide and DNA thereof useful as a neovascular marker
A marker for neovascularization, vascular disease, inflammatory disease, entoptic neovascular disease, reproductive system disease, central nervous system disease and cancer, the method of detection of the marker and a diagnosis kit of the diseases are provided. Additionally, therapeutic agents of the diseases are provided.The expression of KIAA1036 is enhanced in ovarian cancer and large bowel cancer and KIAA1036 expresses in umbilical vein endothelial cell and inhibits DNA synthesis in the cells, cell migrating and lumen formation. Therefore KIAA1036 is useful as a marker for neovascularization, vascular disease, inflammatory disease, entoptic neovascular disease, reproductive system disease, central nervous system disease or cancer. Additionally, KIAA1036 is useful for screening of agonists, antagonists, DNA synthesis inhibitors, cell migrating inhibitors and neovascular inhibitors. The substances obtained by the screening, KIAA1036 and the antibodies are useful as therapeutic agents the above disease.
Owner:TOHOKU UNIV +1
Phenolic Hydrazone Macrophage Migration Inhibitory Factor Inhibitors
InactiveUS20090170951A1Inhibit migrationInhibitory activityBiocideSenses disorderAbnormal tissue growthAutoimmune condition
Provided are various compounds of Formula (I): Also provided are pharmaceutical compositions comprising the above compounds. Additionally, methods of inhibiting macrophage migration inhibitory factor (MIF) activity in a mammal are provided, as are methods of treating or preventing inflammation in a mammal. Further provided are methods of treating a mammal having sepsis, septicemia, and / or endotoxic shock. Also provided are methods of treating a mammal having an autoimmune disease, and methods of treating a mammal having a tumor.
Owner:THE FEINSTEIN INST FOR MEDICAL RES
Preparation method and use of medicine over-expressing PCNP gene
ActiveCN107630027AGrowth inhibitionPromote apoptosisGenetic material ingredientsAntineoplastic agentsEnzyme digestionRestriction enzyme digestion
The invention provides a preparation method and a use of a medicine over-expressing a PCNP gene. The medicine includes a plasmid over-expressing the PCNP gene and a PCNP protein obtained through the over-expression of the PCNP gene. The construction method of the plasmid over-expressing the PCNP gene comprises the following steps: designing a primer according to the sequence of the PCNP gene, andcarrying out PCR amplification on a target gene; carrying out enzyme digestion on restriction enzyme digestion sites Xho I and Kpn I in a GV230 vector to form a linearized GV230 vector; and connectingthe target gene with the linearized GV230 vector to construct a GV230-PCNP vector which is the plasmid over-expressing the PCNP gene. When the medicine over-expressing the PCNP gene is used in humanneuroblastoma cells, the overexpression of the PCNP gene in the human neuroblastoma cells can promote apoptosis, inhibit cell growth, inhibit cell migration and inhibit the growth of human neuroblastomas.
Owner:吴东栋 +8
Enzymatically activatable peptide-redox modulator conjugates and use thereof
Disclosed are peptides capable of enzymatically-induced self-assembly to which is conjugated a redox modulator. These peptides are enzymatically responsive hydrogelators, and they can be used to form pericellular hydrogels / nanofibrils upon exposure to target cells that secrete or express a surface bound ectoenzyme having hydrolase activity suitable to induce peptide gelation. These materials, and compositions containing the same, can be used for inhibiting cancer cell migration, inhibiting cancer cell survival, and / or inhibiting cancer cell growth.
Owner:BRANDEIS UNIV
Therapeutic Molecules and Methods-1
InactiveUS20100323999A1Good effectAntibacterial agentsOrganic active ingredientsDiseaseCombination therapy
Owner:MORAND ERIC FRANCIS +2
Application of alantolactone serving as anti-angiogenesis drug
InactiveCN107260724AAnti-angiogenicGenerate efficientlyOrganic active ingredientsSkeletal disorderTube formationSignalling molecules
The invention relates to new application of alantolactone, in particular to application of the alantolactone serving as an anti-angiogenesis drug. The application has the advantages that the activity of an HUVEC (Human Umbilical Vein Endothelial Cell) is detected through a CCK-8 method, and a cell mobility inhibition experiment, a cell migration inhibition experiment, a tube formation inhibition experiment, an in-vivo anti-angiogenesis activity experiment and the like show that the alantolactone can effectively resist angiogenesis. The application shows that the alantolactone has an inhibition effect on an MDA-MB-231 breast tumor and has a prospect of treating a breast cancer. A first research on a VEGFR2 and downstream signal passageway shows that the alantolactone can obviously inhibit phosphorylation of the VEGFR2 and also obviously inhibit phosphorylation of VEGFR2 downstream signal molecules including PLC(gamma)1, FAK, Src and AKT.
Owner:SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE
Pharmaceutical application of pawpaw total triterpenes
InactiveCN111759896AInhibit apoptosisImprove mobilityDermatological disorderPlant ingredientsTriterpeneApoptosis
The invention discloses pharmaceutical application of pawpaw total triterpenes. The invention specifically comprises application of pawpaw total triterpenes in preparing medicines for promoting cell proliferation and cell migration of human skin fibroblast HDF with UVB injury and inhibiting cell apoptosis, application in preparing medicines for promoting cell proliferation and cell migration of human umbilical vein endothelial cells HUVECs with UVB injury and inhibiting cell apoptosis, application in preparing medicines for treating postoperative cut injury wound healing and application in preparing medicines for treating injured skin regeneration and repair. The pawpaw total triterpenes have a remarkable treatment effect.
Owner:CHINA THREE GORGES UNIV
Method for diagnosis, prognosis or treatment of acute coronary syndrome (ACS) comprising measurement of plasma concentration of macrophage migration inhibitory factor (MIF)
ActiveUS20140234861A1Immobilised enzymesBioreactor/fermenter combinationsBlood plasmaPlasma concentration
A method for diagnosing acute coronary syndrome (ACS) in a subject, the method comprising measuring plasma macrophage migration inhibitory factor (MIF) concentration in a sample from the subject, and diagnosing ACS when the subject plasma MIF concentration is greater than a reference plasma MIF concentration, wherein the sample is taken less than 4 hours after symptom onset. The invention also relates to a method for prognosing ACS in a subject, the method comprising measuring plasma MIF concentration in a sample from the subject, diagnosing ACS when the subject plasma MIF concentration is greater than a reference plasma MIF concentration, and prognosing the magnitude of ACS from the subject plasma MIF concentration. Also provided is a method of treating ACS in a subject, a device, a kit, and a cardiac biomarker related to the methods of diagnosing and prognosing ACS.
Owner:ALFRED HEALTH +1
Pyrazole-Containing Macrophage Migration Inhibitory Factor Inhibitors
In one aspect, the invention comprises compounds that bind and inhibit macrophage migration inhibitory factor. In another aspect, the invention provides methods of treating inflammatory disease, neurological disorders and cancer using the compounds of the invention.
Owner:YALE UNIV
Tumor marker aquaporin 2 protein and application thereof
PendingUS20220299516A1Cell receptors/surface-antigens/surface-determinantsPeptide/protein ingredientsParanasal Sinus CarcinomaHead and neck
Provided are tumor marker aquaporin 2 protein and an application thereof, belonging to the fields of tumor detection and molecular targeted therapy. Embodiments include applications of the aquaporin 2 protein in the following functions: (1) as a new tumor marker used for the early diagnosis and prognostic determination of malignant tumors including head and neck squamous cell carcinoma, kidney cancer and prostate cancer; (2) inhibiting tumor cell proliferation; (3) inhibiting tumor cell migration; (4) inhibiting animal transplant tumor model growth. Targeted therapy which uses the aquaporin 2 protein as a biomarker, as in the embodiments of the present invention, provides new ideas for the treatment of malignant tumors such as head and neck squamous cell carcinoma, kidney cancer and prostate cancer.
Owner:NANJING ANJI BIOLOGICAL TECH CO LTD
Preparation and application of a drug for overexpressing PCNP gene
ActiveCN107630027BGrowth inhibitionPromote apoptosisGenetic material ingredientsAntineoplastic agentsApoptosisRestriction Enzyme Cleavage Site
The invention provides the preparation and use of a drug overexpressing PCNP gene. The medicine includes a plasmid overexpressing PCNP gene and PCNP protein obtained by overexpressing PCNP gene. The construction method of the plasmid overexpressing PCNP gene, which comprises the following steps: according to the PCNP gene sequence, design primers, PCR amplify the target gene; carry out restriction enzyme cutting site Xho I and Kpn I in the GV230 vector. , to form a linearized GV230 vector; the target gene is connected with the linearized GV230 vector to construct a GV230-PCNP vector, which is a plasmid that overexpresses the PCNP gene. When the drug overexpressing PCNP gene is used in human neuroblastoma, the overexpression of PCNP gene in human neuroblastoma can promote cell apoptosis, inhibit cell growth, inhibit cell migration, and inhibit the growth of human neuroblastoma. grow.
Owner:吴东栋 +8
Method for diagnosis, prognosis or treatment of acute coronary syndrome (ACS) comprising measurement of plasma concentration of macrophage migration inhibitory factor (MIF)
A method for diagnosing acute coronary syndrome (ACS) in a subject, the method comprising measuring plasma macrophage migration inhibitory factor (MIF) concentration in a sample from the subject, and diagnosing ACS when the subject plasma MIF concentration is greater than a reference plasma MIF concentration, wherein the sample is taken less than 4 hours after symptom onset. The invention also relates to a method for prognosing ACS in a subject, the method comprising measuring plasma MIF concentration in a sample from the subject, diagnosing ACS when the subject plasma MIF concentration is greater than a reference plasma MIF concentration, and prognosing the magnitude of ACS from the subject plasma MIF concentration. Also provided is a method of treating ACS in a subject, a device, a kit, and a cardiac biomarker related to the methods of diagnosing and prognosing ACS.
Owner:ALFRED HEALTH +1
Pharmaceutical Agents for Preventing Metastasis of Cancer
This invention relates to a pharmaceutical agent for preventing metastasis of cancer, which comprises a substance that inhibits expression of macrophage migration inhibitory factor (MIF). Such substance includes siRNA of MIF.
Owner:HVC STRAGETIC RES INST
Tumor marker AQUAPORIN2 protein and application thereof
ActiveCN112535726APrevent proliferationInhibit migrationCell receptors/surface-antigens/surface-determinantsPeptide/protein ingredientsParanasal Sinus CarcinomaCarcinoma prostate
The invention discloses a tumor marker AQUAPORIN2 protein and application thereof, and belongs to the field of tumor detection and molecular targeted therapy. The invention comprises the application of the AQUAPORIN2 protein in the following functions: (1) serving as a new tumor marker for early diagnosis and prognosis effect judgment of malignant tumors including head and neck squamous carcinoma,kidney cancer and prostate cancer; (2) inhibiting tumor cell proliferation; (3) inhibiting tumor cell migration; and (4) inhibiting growth of an animal transplantation tumor model. The targeted therapy with the AQUAPORIN2 protein as a biomarker provides a new idea for treatment of malignant tumors such as head and neck squamous carcinoma, kidney cancer and prostate cancer.
Owner:NANJING ANJI BIOLOGICAL TECH CO LTD
Preparation method of dandelion extract and application thereof
InactiveCN113577123ASimple extraction processHigh extraction rateAntipyreticAnalgesicsBiotechnologyOrganic acid
The invention provides a preparation method of a dandelion extract and the application of the dandelion extract in treatment or prevention of esophageal cancer. The preparation method comprises the following steps: (1) adding water and a cellulase solution into dandelion powder to activate, decocting, filtering out decoction, and concentrating into extract; and (2) diluting the extract obtained in the step (1), and concentrating and purifying by using a D101 macroporous resin column. According to the invention, the extraction rate and purification efficiency of organic acid are improved, and the dandelion extract has obvious prevention and treatment effects on inflammatory mice, and has good proliferation and cell migration inhibition capability on esophageal cancer cells.
Owner:JIANGSU OCEAN UNIV
Pyrazole-containing macrophage migration inhibitory factor inhibitors
In one aspect, the invention comprises compounds that bind and inhibit macrophage migration inhibitory factor. In another aspect, the invention provides methods of treating inflammatory disease, neurological disorders and cancer using the compounds of the invention.
Owner:YALE UNIV
Treatment of sepsis and inhibition of mif by d-t4
InactiveUS20110136911A1Shorten the pathMinimize consequencesAntibacterial agentsOrganic active ingredientsDiseaseDextrothyroxine
Methods and compositions are disclosed for the use of dextrothyroxine (D-T4) to treat sepsis, inflammation, and conditions and diseases in which it is desirable to inhibit macrophage migration inhibitory factor (MIF).
Owner:THE FEINSTEIN INST FOR MEDICAL RES
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com